Core Viewpoint - The innovative drug concept stocks have shown significant activity, with Chengdu Xian Dao and Chengda Pharmaceutical both rising over 10% following a meeting by the National Medical Insurance Administration regarding the evaluation of innovative drugs and medical devices [1] Group 1: Stock Performance - Chengdu Xian Dao and Chengda Pharmaceutical both experienced stock increases exceeding 10% [1] - Other companies such as Bai Ao Tai, Sai Sheng Pharmaceutical, Li Zhu Group, Hai Te Biological, Chen Xin Pharmaceutical, and Jian Kang Yuan saw stock rises of over 5% [1] Group 2: Regulatory Developments - The National Medical Insurance Administration held the first session of a series of discussions focused on supporting innovative drugs and medical devices [1] - The discussions centered on the topic of conducting comprehensive value assessments for innovative drugs and medical devices [1]
创新药概念股反复活跃 成都先导、诚达药业双双涨超10%